Down 35% This Year, Is This Small-Cap Stock a Buy?
Gene-editing specialist Editas Medicine (NASDAQ: EDIT) has had a challenging 2022, even compared to the struggling stock market. The company's shares are down 35% this year and nearly 60% over the past 12 months. If the company can turn things around, its recent struggles merely represent an opportunity to get in on a discount.
Before pressing the buy button, however, let's consider whether Editas Medicine has what it takes to rebound from its woes.
Source Fool.com